Equity · Healthcare
TECH
NASDAQBio-Techne (TECH)
The line runs $72 on 29 July through $72.30 on 7 August, on a scale from $71.9 to $72.3. Days the market did not trade hold the previous close, flat.
- Market cap
- $11.3B
- P/E (TTM)
- 62.3
- 52-week range
- $43.30 – $72.30
- Avg volume
- 1.1M
as of Aug 7, 2026
Have Bio-Techne (TECH) insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, no Bio-Techne insider bought or sold shares on the open market; all 18 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 28 Oct 2026, newest Form 4 filing 28 Sep 2026
Buys 0Sells 0Other filings 18
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 28 Sep 2026 | HIGGINS JOHN LDirector | Option exercise | 15,940 | |
| 28 Sep 2026 | HIGGINS JOHN LDirector | Tax withheld | 5,562 | $403K |
| 22 Sep 2026 | BAUMGARTNER ROBERT VDirector | Option exercise | 15,940 | |
| 22 Sep 2026 | BAUMGARTNER ROBERT VDirector | Tax withheld | 5,559 | $403K |
| 15 Aug 2026 | Herr Amy E.Director | Option exercise | 589 | |
| 15 Aug 2026 | Herr Amy E.Director | Tax withheld | 213 | $15K |
| 15 Aug 2026 | Crouse Steven C.President - Diag & Spatial Bi | Option exercise | 5,423 | |
| 15 Aug 2026 | Crouse Steven C.President - Diag & Spatial Bi | Tax withheld | 1,947 | $141K |
| 15 Aug 2026 | Bohnen ShaneSVP - General Counsel | Option exercise | 4,350 | |
| 15 Aug 2026 | Bohnen ShaneSVP - General Counsel | Tax withheld | 1,343 | $97K |
| 15 Aug 2026 | Geist WilliamPRESIDENT, PROTEIN SCIENCES | Option exercise | 6,416 | |
| 15 Aug 2026 | Geist WilliamPRESIDENT, PROTEIN SCIENCES | Tax withheld | 1,976 | $143K |
Showing the 12 most recent of 18 compensation filings in this window. The figures above count all of them.
Which funds hold Bio-Techne (TECH)?
14 of the 45 institutional funds we track reported a Bio-Techne position for the quarter ended 30 Jun 2026 — a combined $471.2M; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Maverick Capital | Trimmed | 1,535,610 | $108.5M | −67.6% |
| Millennium Management | New position | 989,033 | $69.9M | |
| Citadel Advisors | Added | 965,918 | $68.2M | +2,125.5% |
| Tudor Investment Corp | New position | 943,287 | $66.6M | |
| Balyasny Asset Management | New position | 836,870 | $59.1M | |
| Soros Fund Management | New position | 535,400 | $37.8M | |
| Man Group | Added | 360,000 | $25.4M | +5,404.6% |
| D. E. Shaw & Co. | New position | 228,479 | $16.1M | |
| Marshall Wace | Held (±25%) | 89,484 | $6.3M | −4.1% |
| Two Sigma Investments | Held (±25%) | 69,625 | $4.9M | +5.3% |
Showing the 10 largest of 14 reported positions. The figures above count all of them.
Have members of Congress traded Bio-Techne (TECH)?
The most recent congressional trade disclosed in Bio-Techne is a purchase by April McClain Delaney (house, MD), dated 05 Dec 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 05 Dec 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | $1K–$15K | 31 days |
| 22 Oct 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | $1K–$15K | 13 days |
| 01 Aug 2025 | April McClain Delaneyhouse · Democrat–MD | Sale | $1K–$15K | 32 days |
| 26 May 2025 | April McClain Delaneyhouse · Democrat–MD | Sale | $1K–$15K | 37 days |
| 29 Apr 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | $1K–$15K | 3 days |
| 09 Apr 2025 | April McClain Delaneyhouse · Democrat–MD | Purchase | $1K–$15K | 23 days |
| 08 Apr 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | $1K–$15K | 30 days |
| 01 Apr 2025 | Julie Johnsonhouse · Democrat–TX | Sale | $1K–$15K | 43 days |
What has been filed or recorded for Bio-Techne (TECH)?
The filings we hold for Bio-Techne, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 22 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 22 Sep 2026 | Fails to deliver | Shares failed to deliver | 48,379 shares | $3.5M notional · 0.031% of shares out |
| 21 Sep 2026 | Fails to deliver | Shares failed to deliver | 1,101 shares | $80K notional · 0.001% of shares out |
| 18 Sep 2026 | Fails to deliver | Shares failed to deliver | 2,696 shares | $195K notional · 0.002% of shares out |
| 14 Sep 2026 | Fails to deliver | Shares failed to deliver | 33 shares | $2K notional · <0.001% of shares out |
| 30 Jun 2026 | Annual report | FY 2026 reported | EPS $1.16 | Revenue $1.22B |
| 30 Jun 2026 | Financials | Revenue | $1.2B | fiscal year |
| 30 Jun 2026 | Financials | Net income to common shareholders | $181.8M | fiscal year |
| 30 Jun 2026 | Financials | Diluted EPS | $1.16 | fiscal year |
| 30 Jun 2026 | Financials | Total assets | $2.6B | at period end |
| 30 Jun 2026 | Financials | Total equity | $2.1B | at period end |
| 31 Mar 2026 | Quarterly earnings | Q3 2026 reported | EPS $0.32 | Revenue $311M |
| 31 Dec 2025 | Quarterly earnings | Q2 2026 reported | EPS $0.24 | Revenue $296M |
| 30 Sep 2025 | Quarterly earnings | Q1 2026 reported | EPS $0.24 | Revenue $287M |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS $0.46 | Revenue $1.22B |
| 31 Mar 2025 | Quarterly earnings | Q3 2025 reported | EPS $0.14 | Revenue $316M |
| 31 Dec 2024 | Quarterly earnings | Q2 2025 reported | EPS $0.22 | Revenue $297M |
| 30 Sep 2024 | Quarterly earnings | Q1 2025 reported | EPS $0.21 | Revenue $289M |
Bio-Techne (TECH): frequently asked questions
What did Bio-Techne shares close at?
Bio-Techne closed at $72.30 on 7 Aug 2026, up 0.41% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Bio-Techne’s market cap?
Bio-Techne is worth $11.3B by market value as of 7 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Bio-Techne’s P/E ratio?
Bio-Techne has a price-to-earnings ratio of 62.3, as of 7 Aug 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Bio-Techne’s revenue?
Bio-Techne reported revenue of $1.2B for the year ended 30 Jun 2026, as filed with the SEC. See Filings
Have Bio-Techne insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, no Bio-Techne insider bought or sold shares on the open market; all 18 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Bio-Techne?
14 of the 45 funds we track reported a Bio-Techne position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Maverick Capital, Millennium Management and Citadel Advisors. See Funds
Have members of Congress traded Bio-Techne?
Yes. 9 trades in Bio-Techne appear in the congressional disclosures we hold; the latest is a purchase by April McClain Delaney (House, MD) dated 5 Dec 2025, filed 5 Jan 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Bio-Techne last report earnings?
Bio-Techne last reported earnings on 30 Jun 2026 for FY 2026, with EPS of $1.16; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings